drugset / Trial / NCT00372697

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

NCT00372697

Phase 3 Completed 28 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluated the safety and efficacy of an increased frequency of octreotide acetate injections or an increase in dose in partially responsive acromegalic patients with persistently uncontrolled disease.

Timeline

Start
2005-12
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide 30 mg Intramuscular
Subject Octreotide Peptide 60 mg Intramuscular

Indications